Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AH110690 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| AH110690 (18F) Injection | DRUG | All subjects will receive an I.V. dose of \[18F\]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of \[18F\]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv). |
Inclusion Criteria: * The subject meets National Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for clinically probable AD and Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)...
Top 20 of 24 competitors
AH110690 is an investigational small molecule being studied for use in Alzheimer's Disease. It has been evaluated in a Phase 2 clinical trial involving patients with probable Alzheimer's Disease and amnestic mild cognitive impairment, as well as healthy volunteers, to assess brain uptake and safety.
AH110690 is being developed by GE HealthCare Technologies Inc., which trades under the ticker GEHC. The company is conducting clinical research on this investigational small molecule for Alzheimer's Disease.
AH110690 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that is not yet approved. The completed trial enrolled 78 participants and was uncontrolled, meaning it did not use a control group.
AH110690 has been studied in one clinical trial, identified as NCT00785759. This Phase 2 study, titled 'Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers,' was completed and enrolled 78 participants in Norway.
AH110690 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is a small molecule being developed for Alzheimer's Disease.